TECENTRIQ (atezolizumab)

OFFICE ADMINISTRATION

FDA Approved Indications:
  • Treatment of locally advanced or metastatic urothelial carcinoma in patients who:
    • have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy, OR
    • are not eligible for cisplantin-containing chemotherapy
  • Treatment of metastatic non-small cell lung cancer in patients who have disease progression during or following platinum-containing chemotherapy.  Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq
Patients must meet the following criteria for the indications above:
  • Prescribed by an oncologist, AND
  • Patient is at least 18 years of age, AND
  • Chart note documentation confirms above diagnosis, AND
  • For advance or metastic urothelial carcinoma: the patient has disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy, OR is not eligible for cisplatin-containing chemotherapy
  • For metastic non-small cell lung cancer: the patient has disease progression during or following platinum-containing chemotherapy, AND patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to starting Tecentriq
Dosing:
  • Administer 1200 mg as an IV infusion over 60 minutes every 3 weeks.
Dose Route Frequency
1200 mg IV Every 3 weeks

 

 

Approval:
  • One year
Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone